Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180508 | 0.89 | FASN (0.57) | ALDH1A1FASN | |
| SCHEMBL13890625 | 0.89 | ALDH1A1 (0.47) | ALDH1A1PKMFASN | |
| SCHEMBL4781450 | 0.84 | FASN (0.52) | ALDH1A1FASN | |
| SCHEMBL13890543 | 0.84 | FASN (0.53) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL13890585 | 0.84 | FASN (0.44) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL13890579 | 0.82 | FASN (0.59) | FASN | |
| SCHEMBL4182755 | 0.82 | FASN (0.57) | ALDH1A1SMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL4184508 | 0.82 | FASN (0.58) | FASN | |
| SCHEMBL13890578 | 0.81 | TSHR (0.56) | ALDH1A1SMN1; SMN2TSHRPKMFASN | |
| SCHEMBL13890589 | 0.81 | FASN (0.47) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | ALDH1A1 463/4885SMN1; SMN2 2999/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.